Chong‐De Lu

565 citations
16 papers · 376 · 1 hit paper · h-index 9

Impact in

  • Hepatology top 5%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 11
    • Liver Disease and Transplantation 3
    • Cholangiocarcinoma and Gallbladder Cancer Studies 7

Chong‐De Lu

13 papers receiving 372 citations

Hit Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial 2024 · 64 citations
640+1Years since publication204060

Peers

Chong‐De Lu
Comparison fields: 5 of 51
  • Hepatology 155
  • Cancer Research 141
  • Oncology 101
  • Surgery 118
  • Epidemiology 74
Replace Yannan Bai with:
Yannan Bai China
Kongying Lin China
Wentao Wang China
Erlei Zhang China
Nicolai Aagaard Schultz Denmark
P. Merle United States
Wusheng Lu China
Bing Quan China
Benyam D. Addissie United States
Sayo Kobayashi Japan
Chong‐De Lu relative to Yannan Bai China Yannan Bai's profile →
Citations per field
00.5×
Yannan Bai · 1×
Citations per year

Countries citing papers authored by Chong‐De Lu

Since Specialization
Citations

This map shows the geographic impact of Chong‐De Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chong‐De Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chong‐De Lu more than expected).

Fields of papers citing papers by Chong‐De Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chong‐De Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chong‐De Lu. The network helps show where Chong‐De Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside Chong‐De Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chong‐De Lu Line = papers co-authored together Chong‐De Lu links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1 2011132
2
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Hit paper breakdown →
202464
3 201358
4 201343
5 201020
6 201516
7 201415
8 20199
9 20238
10 20235
11 20203
12 20242
13 20091
14 20240
15 20250
16 20230

About Chong‐De Lu

Chong‐De Lu is a scholar working on Hepatology, Surgery, Epidemiology, Pathology and Forensic Medicine and Cancer Research, having authored 16 papers that have together received 376 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Mechanisms and Therapy (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Liver Disease and Transplantation (3 papers), MicroRNA in disease regulation (2 papers), Cancer, Lipids, and Metabolism (2 papers) and Hepatitis B Virus Studies (2 papers). The work is most often cited by research in Hepatology (155 citations), Cancer Research (141 citations), Oncology (101 citations), Surgery (118 citations) and Epidemiology (74 citations). Chong‐De Lu has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Xiaohui Fu, Shuqun Cheng, Wei‐Xing Guo, Xiaoping Yao, Wan Yee Lau, Jie Xue, Dong Xie, Hongwei Zhang, Hui Dong and Jiang‐Sha Zhao. Their work appears in journals such as Nature Medicine, International Journal of Surgery, Journal of Hepatology, BioScience Trends and European Journal of Gastroenterology & Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact